In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it…
Certain medications and health factors could increase your risk of side effects when taking LEQEMBI™ and other monoclonal antibody drugs for Alzheimer’s. Here’s what…
Phil Gutis, a career reporter and writer living with early-onset Alzheimer’s, participated in the clinical trials for the first-ever disease-modifying Alzheimer’s drug. Now, he…
A new disease-modifying Alzheimer’s drug, lecanemab — which will be distributed under the brand name Leqembi — today secured FDA approval. Today, the Food…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD, showing the drug is as safe as the placebo with improvements…
A second patient has died of brain bleeds — an anti-amyloid side effect — during the clinical trial extension of Eisai’s Alzheimer’s treatment lecanemab…
Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…